Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852620 | 0.88 | MAPT (0.54) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL2087722 | 0.88 | MAPT (0.54) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| Imidazole SCHEMBL28724682 | 0.79 | LMNA (0.70) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| Imidazole SCHEMBL2061987 | 0.79 | LMNA (0.70) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| Benzoquinone SCHEMBL27678980 | 0.79 | ALDH1A1 (0.32) | CYP3A4LMNAALDH1A1FKBP5ACVR1 | |
| SCHEMBL8624 | 0.77 | CYP3A4 (0.49) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL13166532 | 0.76 | CYP3A4 (0.47) | CYP3A4MAPTKDM4ELMNAAXL | |
| Imidazole SCHEMBL167669 | 0.75 | CYP3A4 (0.41) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| Phenanthrene SCHEMBL28829508 | 0.75 | CYP3A4 (0.54) | CYP3A4MAPTKDM4ELMNAALDH1A1 | |
| Imidazole SCHEMBL27749802 | 0.74 | ALDH1A1 (0.56) | CYP3A4MAPTKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106557-A1 | Peptide ligands for prostate specific antigen | LICENTIA LTD. (FI) | 2004-06-03 | — | — | US | claimed |
| JP-2004509976-A | — | — | 2004-04-02 | — | — | JP | claimed |
| EP-1332152-A1 | PEPTIDE LIGANDS FOR PROSTATE SPECIFIC ANTIGEN | Licentia Ltd. (FI) | 2003-08-06 | — | — | EP | claimed |
| WO-2002026777-A1 | PEPTIDE LIGANDS FOR PROSTATE SPECIFIC ANTIGEN | LICENTIA LTD. (FI) | 2002-04-04 | — | — | WO | claimed |
| US-20230242625-A1 | PANDEMIC-PREPAREDNESS COCKTAIL TO FIGHT CORONAVIRUS OUTBREAKS | THE PENN STATE RESEARCH FOUNDATION | 2023-08-03 | — | — | US | disclosed |
| US-20220162276-A1 | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER | CALVIRI, INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2021252901-A2 | PANDEMIC-PREPAREDNESS COCKTAIL TO FIGHT CORONAVIRUS OUTBREAKS | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11168121-B2 | Identification and use of novopeptides for the treatment of cancer | CALVIRI, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210310008-A1 | PARN AS A BIOMARKER AND THERAPEUTIC TARGET | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-11020482-B2 | Methods and compositions related to inhibition of viral entry | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200215191-A1 | METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY | THE UNIVERSITY OF UTAH | 2020-07-09 | — | — | US | disclosed |
| US-20200191787-A1 | APPLICATION OF ANTI-CD39L3 ANTIBODIES FOR USE IN DISEASE DIAGNOSTICS AND IMAGING | VANDERBILT UNIVERSITY | 2020-06-18 | — | — | US | disclosed |
| WO-2002030465-A2 | COMPOSITIONS THAT INHIBIT PROLIFERATION OF CANCER CELLS | UNIVERSITY OF ROCHESTER (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002026777-A1 | PEPTIDE LIGANDS FOR PROSTATE SPECIFIC ANTIGEN | LICENTIA LTD. (FI) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001089565-A1 | METHODS FOR REDUCING TUMOR GROWTH AND METASTASIS BY INHIBITING MCP-1 ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-29 | — | — | WO | disclosed |
| US-5856107-A | Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein | TREGA BIOSCIENCES, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856107-A | Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein | TREGA BIOSCIENCES, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856107-A | Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein | TREGA BIOSCIENCES, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998034112-A1 | COMBINATORIAL LIBRARIES OF IMIDAZOL-PYRIDO-INDOLES AND IMIDAZOL-PYRIDO-BENZOTHIOPHENE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034112-A1 | COMBINATORIAL LIBRARIES OF IMIDAZOL-PYRIDO-INDOLES AND IMIDAZOL-PYRIDO-BENZOTHIOPHENE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020482-B2 | Methods and compositions related to inhibition of viral entry | HAVCR2, CD4, CD81 | CYP3A4 3395/4885MAPT 3923/4885KDM4E 3846/4885 |
| US-20200215191-A1 | METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY | HAVCR2, CD4, CD81 | CYP3A4 3395/4885MAPT 3923/4885KDM4E 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.